REG - Verici Dx PLC - Notice of AGM and posting of Annual Report

Verici DxAnnouncement

06/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230606:nRSF7012Ba&default-theme=true

RNS Number : 7012B  Verici Dx PLC  06 June 2023

Verici Dx plc

("Verici Dx" or the "Company")

 

Posting of Annual Report & Accounts

and

Notice of Annual General Meeting

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, confirms that the Annual Report and Accounts for the year
ended 31 December 2022 ("2022 Annual Report") and the Notice of the 2023
Annual General Meeting ("AGM") have now been published on the Company's
website: vericidx.com/investors/ (https://vericidx.com/investors/) .

 

The 2022 Annual Report, the Notice of AGM and details for voting by
proxy will be posted to shareholders who have not consented to receive
electronic communications today, on 6 June 2023.

 

The AGM is to be held at 2:00pm on Thursday 29 June 2023 at the Company's
registered offices, at Avon House, 19 Stanwell Road, Penarth, Cardiff, CF64
2EZ and will consider the Resolutions set out in the Notice of AGM.

 

The Company is providing a facility for shareholders to listen in to the AGM
either online or telephonically (in a non-voting capacity) and there will be
an opportunity for shareholders to ask questions. In order to facilitate the
process, the Directors would request that shareholders register for the
meeting and submit questions in advance, before 3:00pm on 27 June 2023. To
register for dial-in details and to submit any questions please contact
Walbrook PR via email at vericidx@walbrookpr.com or call +44 (0)20 7933 8780.

 

Proxy voting

Shareholders will not receive a hard copy form of proxy for the AGM in the
post. Instead, Shareholders will be able to vote electronically using the
link www.signalshares.com (http://www.signalshares.com/) . Proxy votes must
be received no later than 2:00pm on 27 June 2023.

 

Shareholders may request a hard copy form of proxy directly from the
Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the
standard geographic rate and will vary by provider. Calls outside the United
Kingdom will be charged at the applicable international rate. Lines are open
between 09:00 - 17:30, Monday to Friday excluding public holidays in England
and Wales. Alternatively, shareholders can vote by downloading the new app,
LinkVote+, on Apple App Store or Google Play and following the instructions.

 

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 Walbrook PR Limited                                      Tel: +44 20 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Stephanie Cuthbert /                      Mob: +44 7980 541 893 / +44 7796 794 663 /

 Sam Allen                                                07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

Verici Dx's two lead products are Tutivia™, a post-transplant test focused
upon acute cellular rejection, including sub-clinical rejection and
Clarava™, a pre-transplant prognosis test for the risk of early acute
rejection. These products seek to measure how a patient is likely to respond,
and is responding, to a kidney transplant. These products are underpinned by
extensive patented and published scientific research from the leading Mount
Sinai Medical Center, for which the Company holds an exclusive worldwide
licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAEELFBXQLFBBQ